Study of HLX43 for advanced stomach or junction cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called HLX43 (an antibody-drug conjugate targeting PD-L1) for people with advanced stomach or gastroesophageal junction cancer that has progressed after at least one prior treatment. It aims to see if it can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You have advanced or metastatic stomach or gastroesophageal junction cancer that has gotten worse after at least one standard treatment.
- You have at least one tumor that can be measured on a scan.
- You are willing to provide a tumor sample (from a past biopsy or a new one) for testing.
- You have a good performance status (able to care for yourself).
- You have not had certain prior cancer treatments or certain health conditions listed in the full criteria.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HLX43, that targets a protein called PD-L1 on cancer cells and delivers a chemotherapy-like payload directly to them. It's for people with advanced colorectal cancer that hasn't responded to standard treatments.
This trial tests a new drug called HLX43, given alone or with HLX07, against the standard chemo docetaxel for people with a type of advanced lung cancer called squamous non-small cell lung cancer. It's for patients who have already tried and not responded to platinum chemo and immunotherapy.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug, HLX43, for people with advanced esophageal squamous cell carcinoma that has stopped responding to or cannot tolerate standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests an experimental drug called HLX43 for people with advanced pancreatic cancer that has not responded to at least one previous treatment. The goal is to see if HLX43 can help shrink or control the cancer.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.